Be the first person to write a business review for DPT Laboratories, Ltd.

Dragon Pharmaceutical is looking to build a pharmaceutical empire in the PRC. Headquartered in Canada, the company has production facilities within mainland China that manufacture active pharmaceutical ingredients (APIs), intermediates, and finished formulations. It sells its bulk APIs and intermediates, which are used in antibiotic formulations, both in China and internationally (mainly in India). Its finished products (sold only in China) are primarily injectable cephalosporin antibiotics. In 2007 Dragon Pharmaceutical divested its biotech division in order to focus on its core antibiotic operations. CEO Yanlin Han holds nearly half of the company's stock and is seeking to buy the balance.

DRAXIS Specialty Pharmaceuticals (formerly DRAXIS Health) lights up your insides with its own radiopharmaceuticals, but its main business is making other drug companies' injectable drugs, lotions and pills. The company's larger DRAXIS Pharma unit is a contract manufacturer specializing in liquid and freeze-dried injectable drugs, though it also makes sterile and non-sterile ointments, creams, and other formulations. Another unit, DRAXIMAGE, develops and makes radiopharmaceuticals, such as radioactive iodine, for use in diagnostic and therapeutic nuclear medicine procedures. DRAXIMAGE sells its products mostly in the US and Canada. In 2008 India-based Jubilant Organosys acquired DRAXIS for about $255 million.

Eczacibasi Pharmaceutical and Industrial Investment (formerly Eczacibasi Pharmaceuticals Manufacturing) helps to keep the residents of Turkey healthy. The company provides a variety of pharmaceutical and health care products, including vitamins, diagnostic substances, and personal care items. Eczacibasi Pharmaceutical has interests in prescription drug marketing and manufacturing firms, as well as health care supply distribution firms. It also sells generic drugs through a partnership with Zentiva (part of Sanofi-Aventis). The firm's real estate division invests in commercial properties. Founded in 1952, Eczacibasi Pharmaceutical is a subsidiary of family owned Turkish industrial group Eczacibasi Holding.

Eisai develops, manufactures, and distributes prescription pharmaceuticals, primarily in North America and Japan. Prescription drug sales account for a majority of the company's revenues and are led by Aricept, which treats Alzheimer's disease. Other drugs include Myonal, a muscle relaxant, and AcipHex, an acid reflux and ulcer treatment (sold as Pariet in Japan and Europe). Development programs target neurology, oncology, vascular, and immunological ailments. In Japan the company distributes generic and non-prescription drugs and consumer health products. Eisai also makes food additives and chemicals, in addition to drug manufacturing equipment and systems.

Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US pharmaceutical production arm of Eisai Co., its current product roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anticoagulant Fragmin, and anti-convulsant Zonegran. It also maintains an extensive pipeline of potential drugs to address cancer, epilepsy, and severe infection. Subsidiaries Eisai Research Institute of Boston and Eisai Medical Research conduct drug development efforts in areas including oncology, neurology, and gastrointestinal ailments.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.